EP1663968A1 - Process for the preparation of pure levetiracetam - Google Patents

Process for the preparation of pure levetiracetam

Info

Publication number
EP1663968A1
EP1663968A1 EP04769257A EP04769257A EP1663968A1 EP 1663968 A1 EP1663968 A1 EP 1663968A1 EP 04769257 A EP04769257 A EP 04769257A EP 04769257 A EP04769257 A EP 04769257A EP 1663968 A1 EP1663968 A1 EP 1663968A1
Authority
EP
European Patent Office
Prior art keywords
solvent
levetiracetam
ether
under vacuum
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769257A
Other languages
German (de)
French (fr)
Inventor
Yatendra Kumar
Mohan Prasad
Kaptan Flat No. B-02 Saket Enclave SINGH
Surender Kumar Dhingra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1663968A1 publication Critical patent/EP1663968A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • levetiracetam is (S)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide and is known from U.S. Patent No. 4,943,639.
  • Levetiracetam is used as a protective agent for the treatment and prevention of hypoxic and ischemic type aggressions of the central nervous system. It is also effective in the treatment of epilepsy.
  • 4,943,639 discloses the preparation of levetiracetam by reacting (S)-alpha-ethyl-2-oxo-l-pyrrolidineacetic acid successively with alkylhaloformate and with ammonia.
  • (S)-alpha-ethyl-2-oxo-l-pyrroiidineacetic acid in turn was obtained by the chemical resolution of racemic ( ⁇ )-alpha-ethyl-2-oxo- 1 - pyrrolidineacetic acid.
  • 6,107,492 and 6,124,473 describe the preparation of levetiracetam by optical resolution of the racemic mixture of alpha- ethyl-2-oxo-l-pyrrolidineacetamide through simulated mobile bed chromatography or preparative high performance liquid chromatography.
  • WO 01/64637 discloses the preparation of levetiracetam by asymmetric hydrogenation of (Z) or (E)-2-(2- oxotetrahydro-lH-l-pyrrolyl)-2-butenamide, using a chiral catalyst. Summary of the Invention In one aspect there is provided a process for preparing pure levetiracetam having optical purity more than 99.5%.
  • the process includes obtaining a solution of crude levetiracetam in one or more solvents; removing undissolved material; and recovering the pure levetiracetam having optical purity more than 99.5% from the solution thereof by the removal of the solvent.
  • the solvent may be one or more of ketone, nitrile, hydrocarbon, chlorinated hydrocarbon, ether, cyclic ether or mixtures thereof.
  • the ketone may include one or more of acetone, methyl ethyl ketone and methyl isobutyl ketone.
  • the nitrile may include acetonitrile.
  • the hydrocarbon may include toluene.
  • the chlorinated hydrocarbon may include one or more of methylene chloride and ethylene dichloride.
  • the ether may include one or more of diethyl ether and diisopropyl ether.
  • the cyclic ether may include dioxane and tetrahydrofuran.
  • Removing the solvent may include one or more of distillation, distillation under vacuum, filtration, filtration under vacuum, evaporation, decantation and centrifugation. The process may include further drying of the product obtained.
  • additional/second solvent may be added to residue obtained after removal of the solvent and it may be cooled before filtration to obtain better yields of the pure levetiracetam.
  • additional/second solvent examples include esters such as ethyl acetate, isobutyl acetate and isopropyl acetate; hydrocarbons such as hexane, cyclohexane, toluene and heptane; lower alkyl ethers such as diethyl ether, diisopropyl ether and mixtures thereof.
  • the process may produce the pure levetiracetam having optical purity more than 99.5%. In particular, it may produce the pure levetiracetam having optical purity more than 99.8%.
  • a pharmaceutical composition that includes a therapeutically effective amount of pure levetiracetam having optical purity more than 99.5%; and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the inventors also have developed pharmaceutical compositions that contain the pure levetiracetam having optical purity more than 99.5% for example, more than 99.8%, in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients.
  • the levetiracetam may be prepared by the methods known in the literature. In particular, it may be prepared using the reactions and techniques described in U.S. Patent No. 4,943,639; PCT patent application WO 01/64637; and British patent GB 2225322.
  • the term "crude levetiracetam” includes levetiracetam having optical purity of not less than 90%. In general, the solution of crude levetiracetam may be obtained by dissolving crude levetiracetam in a suitable solvent.
  • such a solution may be obtained directly from a reaction in which levetiracetam is formed.
  • the solvent containing crude levetiracetam may be heated to obtain a solution. It can be heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C.
  • the term "obtaining” includes dissolving, slurrying, stirring or a combination thereof.
  • the pure levetiracetam may be recovered from the solution by a technique which includes, for example, distillation, distillation under vacuum, filtration, filtration under vacuum, evaporation, decantation, and centrifugation.
  • suitable solvent includes any solvent or solvent mixture in which crude levetiracetam is soluble, including, for example, ketone, nitrile, hydrocarbon, chlorinated hydrocarbon and mixtures thereof.
  • a suitable ketone includes one or more of acetone, methyl ethyl ketone and methyl isobutyl ketone.
  • nitrile include acetonitrile.
  • hydrocarbon include toluene and examples of chlorinated hydrocarbons include one or more of methylene chloride and ethylene dichloride.
  • ethers include solvents such as diethyl ether and diisopropyl ether and cyclic ethers such as dioxane, tetrahydrofuran.
  • the undissolved material may be removed by a technique which includes filtration, filtration under vacuum, centrifugation, and decantation. In general, after removing the undissolved material, the resulting solution may be cooled before recovering the pure levetiracetam. The solution may also be concentrated before cooling. Additional or second solvent may be added to residue obtained after concentration and it may be cooled before filtration to obtain better yields of the pure levetiracetam.
  • additional/second solvent examples include esters such as ethyl acetate, isobutyl acetate and isopropyl acetate; hydrocarbons such as hexane, cyclohexane, toluene and heptane; lower alkyl ethers such as diethyl ether, diisopropyl ether and mixtures thereof.
  • Example 1 Preparation of pure levetiracetam Crude levetiracetam (123g, optical purity ⁇ 96.00%) was mixed with acetone (2800ml) and stirred at ambient temperature for 60 minutes. The undissolved material was then filtered through hyflo bed and washed with acetone (200ml). The filtrate and washings were combined and concentrated under vacuum at 35 to 40°C to about 240ml of the volume. To the resulting slurry, ethyl acetate (480ml) was charged and stirred for 20 minutes at ambient temperature. The solid so obtained was filtered and washed with ethyl acetate (100ml). It was dried under vacuum at 40 to 45°C till loss on drying was less than 0.5% to give the pure product. Yield: 108g
  • Example 2 Preparation of pure levetiracetam Crude levetiracetam (lOOg, optical purity ⁇ 98.48%) was mixed with acetone (2300ml) and stirred at ambient temperature for 60 minutes. The undissolved material was then filtered through hyflo bed and washed with acetone (160ml). The filtrate and washings were combined and concentrated under vacuum at 35 to 40°C to about 200ml. Ethyl acetate (200ml) was then charged into the resulting slurry and stirred for 20 minutes at ambient temperature. The solid so obtained was filtered and washed with ethyl acetate (400ml). The wet solid product was dried under vacuum at 40 to 45°C till loss on drying was less than 0.5% to give the pure product. Yield: 87g
  • Example 3 Preparation of pure levetiracetam Crude levetiracetam (36g, optical purity ⁇ 96.00%) was mixed with acetone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to processes for the preparation of pure levetiracetam. The invention also relates to pharmaceutical compositions that include the pure levetiracetam.

Description

PROCESS FORTHE PREPARATION OFPURELEVETIRACETAM Field of the Invention The field of the invention relates to processes for the preparation of pure levetiracetam. The invention also relates to pharmaceutical compositions that include the pure levetiracetam. Background of the Invention Chemically, levetiracetam is (S)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide and is known from U.S. Patent No. 4,943,639. Levetiracetam is used as a protective agent for the treatment and prevention of hypoxic and ischemic type aggressions of the central nervous system. It is also effective in the treatment of epilepsy. U.S. Patent No. 4,943,639 discloses the preparation of levetiracetam by reacting (S)-alpha-ethyl-2-oxo-l-pyrrolidineacetic acid successively with alkylhaloformate and with ammonia. (S)-alpha-ethyl-2-oxo-l-pyrroiidineacetic acid, in turn was obtained by the chemical resolution of racemic (±)-alpha-ethyl-2-oxo- 1 - pyrrolidineacetic acid. U.S. Patent Nos. 6,107,492 and 6,124,473 describe the preparation of levetiracetam by optical resolution of the racemic mixture of alpha- ethyl-2-oxo-l-pyrrolidineacetamide through simulated mobile bed chromatography or preparative high performance liquid chromatography. WO 01/64637 discloses the preparation of levetiracetam by asymmetric hydrogenation of (Z) or (E)-2-(2- oxotetrahydro-lH-l-pyrrolyl)-2-butenamide, using a chiral catalyst. Summary of the Invention In one aspect there is provided a process for preparing pure levetiracetam having optical purity more than 99.5%. The process includes obtaining a solution of crude levetiracetam in one or more solvents; removing undissolved material; and recovering the pure levetiracetam having optical purity more than 99.5% from the solution thereof by the removal of the solvent. The solvent may be one or more of ketone, nitrile, hydrocarbon, chlorinated hydrocarbon, ether, cyclic ether or mixtures thereof. The ketone may include one or more of acetone, methyl ethyl ketone and methyl isobutyl ketone. The nitrile may include acetonitrile. The hydrocarbon may include toluene. The chlorinated hydrocarbon may include one or more of methylene chloride and ethylene dichloride. The ether may include one or more of diethyl ether and diisopropyl ether. The cyclic ether may include dioxane and tetrahydrofuran. Removing the solvent may include one or more of distillation, distillation under vacuum, filtration, filtration under vacuum, evaporation, decantation and centrifugation. The process may include further drying of the product obtained. In another general aspect additional/second solvent may be added to residue obtained after removal of the solvent and it may be cooled before filtration to obtain better yields of the pure levetiracetam. Examples of additional/second solvent include esters such as ethyl acetate, isobutyl acetate and isopropyl acetate; hydrocarbons such as hexane, cyclohexane, toluene and heptane; lower alkyl ethers such as diethyl ether, diisopropyl ether and mixtures thereof. The process may produce the pure levetiracetam having optical purity more than 99.5%. In particular, it may produce the pure levetiracetam having optical purity more than 99.8%. In another aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of pure levetiracetam having optical purity more than 99.5%; and one or more pharmaceutically acceptable carriers, excipients or diluents. The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. Detailed Description of the Invention The inventors have developed a process for the preparation of pure levetiracetam, by obtaining a solution of crude levetiracetam in one or more solvents; removing undissolved material; and recovering the pure levetiracetam having optical purity more than 99.5% from the solution thereof by the removal of the solvent. The inventors also have developed pharmaceutical compositions that contain the pure levetiracetam having optical purity more than 99.5% for example, more than 99.8%, in admixture with one or more solid or liquid pharmaceutical diluents, carriers, and/or excipients. The levetiracetam may be prepared by the methods known in the literature. In particular, it may be prepared using the reactions and techniques described in U.S. Patent No. 4,943,639; PCT patent application WO 01/64637; and British patent GB 2225322. The term "crude levetiracetam" includes levetiracetam having optical purity of not less than 90%. In general, the solution of crude levetiracetam may be obtained by dissolving crude levetiracetam in a suitable solvent. Alternatively, such a solution may be obtained directly from a reaction in which levetiracetam is formed. The solvent containing crude levetiracetam may be heated to obtain a solution. It can be heated from about 30°C to about reflux temperature of the solvent used, for example from about 30°C to about 100°C. The term "obtaining" includes dissolving, slurrying, stirring or a combination thereof. The pure levetiracetam may be recovered from the solution by a technique which includes, for example, distillation, distillation under vacuum, filtration, filtration under vacuum, evaporation, decantation, and centrifugation. The term "suitable solvent" includes any solvent or solvent mixture in which crude levetiracetam is soluble, including, for example, ketone, nitrile, hydrocarbon, chlorinated hydrocarbon and mixtures thereof. A suitable ketone includes one or more of acetone, methyl ethyl ketone and methyl isobutyl ketone. Examples of nitrile include acetonitrile. Examples of hydrocarbon include toluene and examples of chlorinated hydrocarbons include one or more of methylene chloride and ethylene dichloride. Examples of ethers include solvents such as diethyl ether and diisopropyl ether and cyclic ethers such as dioxane, tetrahydrofuran. Mixtures of all of these solvents are also contemplated. The undissolved material may be removed by a technique which includes filtration, filtration under vacuum, centrifugation, and decantation. In general, after removing the undissolved material, the resulting solution may be cooled before recovering the pure levetiracetam. The solution may also be concentrated before cooling. Additional or second solvent may be added to residue obtained after concentration and it may be cooled before filtration to obtain better yields of the pure levetiracetam. Examples of additional/second solvent include esters such as ethyl acetate, isobutyl acetate and isopropyl acetate; hydrocarbons such as hexane, cyclohexane, toluene and heptane; lower alkyl ethers such as diethyl ether, diisopropyl ether and mixtures thereof. The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1: Preparation of pure levetiracetam Crude levetiracetam (123g, optical purity ~ 96.00%) was mixed with acetone (2800ml) and stirred at ambient temperature for 60 minutes. The undissolved material was then filtered through hyflo bed and washed with acetone (200ml). The filtrate and washings were combined and concentrated under vacuum at 35 to 40°C to about 240ml of the volume. To the resulting slurry, ethyl acetate (480ml) was charged and stirred for 20 minutes at ambient temperature. The solid so obtained was filtered and washed with ethyl acetate (100ml). It was dried under vacuum at 40 to 45°C till loss on drying was less than 0.5% to give the pure product. Yield: 108g
Chromatographic purity = 99.99%
Optical purity = 99.95%
Example 2: Preparation of pure levetiracetam Crude levetiracetam (lOOg, optical purity ~ 98.48%) was mixed with acetone (2300ml) and stirred at ambient temperature for 60 minutes. The undissolved material was then filtered through hyflo bed and washed with acetone (160ml). The filtrate and washings were combined and concentrated under vacuum at 35 to 40°C to about 200ml. Ethyl acetate (200ml) was then charged into the resulting slurry and stirred for 20 minutes at ambient temperature. The solid so obtained was filtered and washed with ethyl acetate (400ml). The wet solid product was dried under vacuum at 40 to 45°C till loss on drying was less than 0.5% to give the pure product. Yield: 87g
Chromatograpliic purity = 99.99%
Optical purity = 99.95%
Example 3: Preparation of pure levetiracetam Crude levetiracetam (36g, optical purity ~ 96.00%) was mixed with acetone
(216ml) and refluxed at 56-57°C. The undissolved material was then filtered through hyflo bed and washed with acetone (200ml). The filtrate and washings were combined and cooled to 25°C. The resulting slurry was further stirred for about 1 hour at the same temperature. The solid so obtained was filtered and washed with acetone (18ml). It was dried under vacuum at 40 to 45°C till loss on drying was less than 0.5% to give the pure product.
Yield: 25.2g
Chromatographic purity = 99.79%
Optical purity = 99.84% While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.

Claims

We claim: 1. A process for the preparation of pure levetiracetam having optical purity more than 99.5%, the process comprising; obtaining a solution of crude levetiracetam in one or more solvents; removing undissolved material; and recovering the pure levetiracetam from the solution thereof by the removal of the solvent.
2. The process of claim 1, wherein the solvent comprises one or more of ketone,nitrile, hydrocarbon, chlorinated hydrocarbon, ether, cyclic ether or mixtures thereof.
3. The process of claim 2, wherein the ketone comprises one or more of acetone, methyl ethyl ketone and methyl isobutyl ketone.
4. The process of claim 2, wherein the nitrile is acetonitrile.
5. The process of claim 2, wherein the hydrocarbon is toluene.
6. The process of claim 2, wherein the chlorinated hydrocarbon comprises one or more of methylene chloride and ethylene dichloride.
7. The process of claim 2, wherein the ether comprises one or more of diethyl ether and diisopropyl ether.
8. The process of claim 2, wherein the cyclic ether comprises one or more of dioxane and tetrahydrofuran.
9. The process of claim 1, wherein removing the undissolved material comprises one or more of filtration, filtration under vacuum, decantation and centrifugation.
10. The process of claim 1, wherem removing the solvent comprises one or more of distillation, distillation under vacuum, evaporation, filtration, filtration under vacuum, decantation and centrifugation.
11. The process of claim 10, wherein removing the solvent comprises one or more of distillation and distillation under vacuum.
12. The process of claim 11 further comprising adding second solvent after removing the solvent.
13. The process of claim 12, wherein the second solvent comprises one or more of esters, hydrocarbons, ethers and mixtures thereof.
14. The process of claim 13, wherein the ester comprises one or more of ethyl acetate, isobutyl acetate and isopropyl acetate.
15. The process of claim 13, wherein the hydrocarbon comprises one or more of hexane, cyclohexane, toluene, heptane, and octane.
16. The process of claim 13, wherein the ether comprises one or more of diethyl ether, diisopropyl ether.
17. The process of claim 10, wherein removing the solvent comprises one or more of filtration, filtration under vacuum and centrifugation.
18. The process of claim 17 further comprising cooling before removing the solvent.
19. The process of claim 1 further comprising additional drying of the product obtained.
20. The process of claim 1 further comprising forming the product obtained into a finished dosage form.
21. Pure levetiracetam having optical purity more than 99.5% prepared by the process of claim 1.
22. Pure levetiracetam having optical purity 99.8% or more prepared by the process of claim 1.
23. A pharmaceutical composition comprising a therapeutically effective amount of the pure levetiracetam obtained by the process of claim 1 ; and one or more pharmaceutically acceptable carriers, excipients or diluents.
EP04769257A 2003-09-05 2004-09-02 Process for the preparation of pure levetiracetam Withdrawn EP1663968A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1108DE2003 2003-09-05
PCT/IB2004/002850 WO2005023763A1 (en) 2003-09-05 2004-09-02 Process for the preparation of pure levetiracetam

Publications (1)

Publication Number Publication Date
EP1663968A1 true EP1663968A1 (en) 2006-06-07

Family

ID=34259942

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769257A Withdrawn EP1663968A1 (en) 2003-09-05 2004-09-02 Process for the preparation of pure levetiracetam

Country Status (2)

Country Link
EP (1) EP1663968A1 (en)
WO (1) WO2005023763A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080470A2 (en) * 2006-01-16 2007-07-19 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of levetiracetam
JP2009524658A (en) * 2006-01-24 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド Levetiracetam preparation and method for producing the same
WO2009057137A2 (en) * 2007-08-22 2009-05-07 Alembic Limited A process for the purification of levetiracetam
CN103922988A (en) * 2014-04-29 2014-07-16 苏州天马精细化学品股份有限公司 Method for purifying levetiracetam crude product
CN108329247A (en) * 2018-02-10 2018-07-27 浙江华海药业股份有限公司 A kind of preparation method of small particle size Levetiracetam

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
DE60229267D1 (en) * 2001-08-10 2008-11-20 Ucb Pharma Sa OXOPYRROLIDINE COMPOUNDS, METHOD FOR PRODUCING THESE COMPOUNDS AND THEIR USE FOR THE PRODUCTION OF LEVETIRACETAM AND ANALOGUE
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005023763A1 *

Also Published As

Publication number Publication date
WO2005023763A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
Soloshonok et al. Asymmetric synthesis of novel highly sterically constrained (2S, 3S)-3-methyl-3-trifluoromethyl-and (2S, 3S, 4R)-3-trifluoromethyl-4-methylpyroglutamic acids
TWI673271B (en) Process for preparing btk inhibitors
KR101673634B1 (en) Processes for the preparation of 4-oxo-octahydro-indole-1-carboxylic acid methyl ester and derivatives thereof
CN112739683B (en) Preparation method of brivaracetam and intermediate thereof
KR100666423B1 (en) Process for the preparation of 2r-2-propyloctanoic acid
Wang et al. Synthesis of chiral ferrocenyl aziridino alcohols and use in the catalytic asymmetric addition of diethylzinc to aldehydes
EP2327708A2 (en) Purification method for adefovir dipivoxil
JP2001508446A (en) Asymmetric synthesis and catalysis by chiral heterocyclic compounds
JP2008519046A (en) Process for the preparation of quinoline compounds and products obtained therefrom
EP3063154B1 (en) Cross-coupling of unactivated secondary boronic acids
ZA200601262B (en) Cycloakylaminoacid compounds, processes for making and uses thereof
WO2005023763A1 (en) Process for the preparation of pure levetiracetam
CN106986766B (en) Preparation method of tafluprost
CN113880744A (en) Chiral resolution method of brivaracetam
CN100410248C (en) Modifications of the trometamol salt of R-thioctic acid as well as a process for their production
CN111233689A (en) 13Purification method and preparation method of C-methaoxetine
WO2019036349A1 (en) Directed b-c(sp3)-h iodination and arylation of ketones
CN101743218B (en) Method for producing optically active trans-2-aminocyclohexanol and intermediate of optically active trans-2-aminocyclohexanol
WO2007080470A2 (en) A method for the purification of levetiracetam
WO2021002407A1 (en) Fluoroalkyl group-containing compound and production method therefor
CN101801984A (en) Chiral phosphoramides, chiral N-phosphonimines and methods for forming the same
CN111793017A (en) Preparation method of lactam compound
JP3855295B2 (en) Method for producing bisoxazolines
WO2023143158A1 (en) Phenol derivative, crystal form thereof, and preparation method therefor
CN117843525B (en) Preparation method of (2S, 3R, 4R) -4, 5-dihydroxyisoleucine derivative and intermediate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070330